Clinical Trials · NCT00039026
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 377
- Start date
- Feb 2002
- Locations
- 126 sites, United States
- Primary endpoint
- Change in HbA1c from Baseline to Week 30